33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Frontline brentuximab vedotin and CHP (A+CHP) in patients with peripheral T‐cell lymphoma with less than 10% CD30 expression (SGN35‐032, trial in progress)
    Meeting Abstract

    Jagadeesh, D.; Knowles, S.; Horwitz, S. M.
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • New prognostic score incorporating MTV predicts treatment failure in advanced Hodgkin lymphoma
    Meeting Abstract

    Barrington, S. F.; Kirkwood, A. A.; Pike, L. C.; Guezennec, C.; Li, H.; le Blanc, M.; Poon, D.; Knopp, M. V.; Clifton‐Hadley, L.; Laubach, C.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Outcomes in later‐lines of therapy for relapsed/refractory follicular lymphoma: Results from the international SCHOLAR‐5 study
    Meeting Abstract

    Ghione, P.; Ghesquieres, H.; Bobillo, S.; Patel, A. R.; Kanters, S.; Deighton, K.; Dong, H.; Yang, Y.; Ma, L.; Limbrick‐Oldfield, E. H.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Circulating tumor DNA load and total metabolic tumor volume in diffuse large B cell lymphoma (DLBCL) patients treated by R‐CHOP – From REMARC, a LYSA study
    Meeting Abstract

    Bohers, E.; Delfau‐Larue, M.; Vercellino, L.; Cottereau, A.; Viennot, M.; Viailly, P.; Salles, G.; Tilly, H.; Damaj, G.; Haioun, C.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAs) with stage III or IV Hodgkin lymphoma: A subgroup analysis from the phase 3 ECHELON‐1 study
    Meeting Abstract

    Crosswell, H. E.; LaCasce, A. S.; Bartlett, N. L.; Straus, D. J.; Savage, K. J.; Zinzani, P. L.; Collins, G. P.; Fanale, M. A.; Fenton, K.; Dong, C.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Clinical outcomes and the role of observation in early‐stage follicular lymphoma
    Meeting Abstract

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Kumar, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of adult lymphoma‐associated hemophagocytic lymphohistiocytosis (HLH)
    Meeting Abstract

    Lee, C. Y.; Wills Sanin, B.; Vardhana, S. A.; Moskowitz, A. J.
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • An open‐label trial of oral CA‐4948 an IRAK4 inhibitor combined with ibrutinib in adult patients with relapsed or refractory hematologic malignancies
    Meeting Abstract

    Joffe, E.; Ramchandren, R.; Nowakowski, G.; Rosenthal, A.; Tun, H. W.; Lunning, M.; Mead, M. D.; Martinez, E.; von Roemeling, R.; Leslie, L.
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (CHL)
    Meeting Abstract

    LaCasce, A. S.; Dockter, T.; Ruppert, A.; Kostakoglu, L.; Schöder, H.; Hsi, E. D.; Bogart, J. A.; Cheson, B. D.; Wagner‐Johnston, N. D.; Abramson, J. S.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Selpercatinib (LOXO-292) in patients with RET-fusion+ non small-cell lung cancer (NSCLC)
    Meeting Abstract

    Goto, K.; Oxnard, G.; Tan, Dswsw; Loong, H. H. F.; Bauer, T. T.; Gainor, J.; McCoach, C.; Gautschi, O.; Besse, B.; Cho, B. C.; more...
    Pneumologie (2021)

    Fulltext@MSK | Save